Back to all presentations
Redeye Interview with CEO Kristina Torfgård
Alzinova's CEO Kristina Torfgård was interviewed on October 13, 2021 by Redeye’s Life Science analyst Kevin Sule.
In this interview, Kristina talks about the initiation of the clinical phase 1b study with the lead candidate ALZ-101, the timetable for the future and the development of the preclinical candidate ALZ-201.
Click the image below to see the interview (in Swedish).
